Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY) of Cambridge said today that it missed its goal but saw a “statistically significant reduction” in the incidence of a life-threatening lung disease in lung transplant patients with respiratory syncytial virus (RSV) infection in a Phase 2b trial of a drug candidate.
